Fewer patients experienced a first hospital admission for any indication and for serious adverse events while on semaglutide.

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Recent research has found that semaglutide injections, which also include controversial weight loss drug Ozempic, can reduce ...

Ozempic (semaglutide) and Victoza (liraglutide ... Both drugs are given as a subcutaneous injection (an injection under your skin). The key difference between Ozempic and Victoza is how often ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

The drug was given as a subcutaneous injection every four weeks in the ... of Novo Nordisk’s once-weekly GLP-1 agonist Wegovy (semaglutide), which the company reckons will drive its obesity ...